RLS Global AB has signed an agreement with Region Stockholm and Gotland for ChloraSolv®

Report this content

RLS Global AB is pleased to inform that ChloraSolv is awarded on the current tender agreement in Region Stockholm and Gotland. The agreement is effective August 15th, 2020. The clinical evaluation has been very positive and ChloraSolv is now available to all healthcare providers in the region such as inpatient- and outpatient care, primary care, and private care providers. The agreement is the largest in Sweden in wound care.

“Now we see another result of the intensive work that RLS has completed in the autumn 2019 and spring 2020 to gain access to the different regions in Sweden, says Karin Fischer, CEO RLS Global. Of course, this is a very important agreement for RLS as it is the country’s largest. This is an important milestone for us in our continued work, continues Karin”.

Trading place and Certified Advisor

RLS Global’s shares has been listed on the Nasdaq First North Growth Market since May 17th, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

Contact information

Karin Fischer, CEO
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
Telephone: +46 31 780 68 20

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop product within wound care. RLS Global has a portfolio of strong brands, including ChloraSolv® and CariSolv®. The company is listed on Nasdaq First North Growth Market with Redeye Aktiebolag as the Certified Advisor,
phone: +46 8 121 576 90, email:
certifiedadviser@redeye.se. Read more at www.rls.global